Kilitch Drugs (India) Beheer

Beheer criteriumcontroles 3/4

Momenteel beschikken wij niet over voldoende informatie over de CEO.

Belangrijke informatie

Mukund Mehta

Algemeen directeur

n/a

Totale compensatie

Percentage CEO-salaris	n/a
Dienstverband CEO	32.5yrs
Eigendom CEO	7.1%
Management gemiddelde ambtstermijn	2.5yrs
Gemiddelde ambtstermijn bestuur	7.2yrs

Recente managementupdates

Shareholders Would Not Be Objecting To Kilitch Drugs (India) Limited's (NSE:KILITCH) CEO Compensation And Here's Why

Sep 23

Recent updates

Kilitch Drugs (India) Limited (NSE:KILITCH) Not Flying Under The Radar

Jul 23

Here's Why Kilitch Drugs (India) (NSE:KILITCH) Can Manage Its Debt Responsibly

Mar 05

Kilitch Drugs (India) Limited (NSE:KILITCH) Looks Just Right With A 26% Price Jump

Feb 02

We Ran A Stock Scan For Earnings Growth And Kilitch Drugs (India) (NSE:KILITCH) Passed With Ease

Jan 30

Investors Shouldn't Be Too Comfortable With Kilitch Drugs (India)'s (NSE:KILITCH) Earnings

Nov 17

Shareholders Would Not Be Objecting To Kilitch Drugs (India) Limited's (NSE:KILITCH) CEO Compensation And Here's Why

Sep 23

These 4 Measures Indicate That Kilitch Drugs (India) (NSE:KILITCH) Is Using Debt Reasonably Well

Sep 08

Here's Why Kilitch Drugs (India) (NSE:KILITCH) Has Caught The Eye Of Investors

May 05

Kilitch Drugs (India) (NSE:KILITCH) Could Easily Take On More Debt

Jul 06

Here's Why I Think Kilitch Drugs (India) (NSE:KILITCH) Might Deserve Your Attention Today

Apr 08

These 4 Measures Indicate That Kilitch Drugs (India) (NSE:KILITCH) Is Using Debt Reasonably Well

Dec 17

Is Kilitch Drugs (India) (NSE:KILITCH) Using Too Much Debt?

Mar 21

Should Weakness in Kilitch Drugs (India) Limited's (NSE:KILITCH) Stock Be Seen As A Sign That Market Will Correct The Share Price Given Decent Financials?

Feb 13

Is Kilitch Drugs (India) (NSE:KILITCH) Weighed On By Its Debt Load?

Dec 03

Does Kilitch Drugs (India) Limited (NSE:KILITCH) Have A Place In Your Dividend Stock Portfolio?

Aug 20

Should Weakness in Kilitch Drugs (India) Limited's (NSE:KILITCH) Stock Be Seen As A Sign That Market Will Correct The Share Price Given Decent Financials?

Jul 16

Analyse CEO-vergoeding

Hoe is Mukund Mehta's beloning veranderd ten opzichte van Kilitch Drugs (India)'s winst?
Datum	Totale vergoeding	Salaris	Bedrijfswinsten
Sep 30 2024	n/a	n/a	₹165m
Jun 30 2024	n/a	n/a	₹126m
Mar 31 2024	n/a	n/a	₹146m
Dec 31 2023	n/a	n/a	₹146m
Sep 30 2023	n/a	n/a	₹140m
Jun 30 2023	n/a	n/a	₹117m
Mar 31 2023	₹6m	₹6m	₹104m
Dec 31 2022	n/a	n/a	₹98m
Sep 30 2022	n/a	n/a	₹85m
Jun 30 2022	n/a	n/a	₹83m
Mar 31 2022	₹6m	₹6m	₹74m
Dec 31 2021	n/a	n/a	₹52m
Sep 30 2021	n/a	n/a	₹63m
Jun 30 2021	n/a	n/a	₹62m
Mar 31 2021	₹6m	n/a	₹37m
Dec 31 2020	n/a	n/a	₹17m
Sep 30 2020	n/a	n/a	₹4m
Jun 30 2020	n/a	n/a	-₹3m
Mar 31 2020	₹6m	n/a	₹8m

Compensatie versus markt: Er zijn onvoldoende gegevens om vast te stellen of de totale vergoeding van Mukund redelijk is in vergelijking met bedrijven van vergelijkbare omvang in de Indian markt.

Compensatie versus inkomsten: De vergoeding van Mukund is het afgelopen jaar in lijn geweest met de bedrijfsprestaties.

CEO

Mukund Mehta (71 yo)

32.5yrs

Tenure

₹6,000,000

Compensatie

Mr. Mukund Prataprai Mehta, B.Com, LL B., serves as the Chairman and Managing Director at Kilitch Drugs (India) Limited and has been its Executive Director since May 12, 1992. Mr. Mehta served as the Compl...

Leiderschapsteam

Naam	Positie	Tenure	Compensatie	Eigendom
Mukund Mehta	Executive Chairman & MD	no data	₹6.00m	7.09% ₹ 352.5m
Mira Mehta	Managing Director	less than a year	₹2.40m	5.23% ₹ 259.9m
Bhavin Mehta	Whole-time Director	no data	₹8.40m	15.69% ₹ 779.8m
Sunil Jain	Chief Financial Officer	3.7yrs	₹1.50m	geen gegevens
Tajouddin Ansari	VP-Marketing & Operation	no data	geen gegevens	geen gegevens
Rajesh Khatri	General Manager - Administration	no data	geen gegevens	geen gegevens
Pushpa Nyoupane	Company Secretary & Compliance Officer	2.5yrs	geen gegevens	geen gegevens

2.5yrs

Gemiddelde duur

48yo

Gemiddelde leeftijd

Ervaren management: Het managementteam van KILITCH wordt beschouwd als ervaren (gemiddelde ambtstermijn 2.5 jaar).

Bestuursleden

Naam	Positie	Tenure	Compensatie	Eigendom
Mukund Mehta	Executive Chairman & MD	32.5yrs	₹6.00m	7.09% ₹ 352.5m
Mira Mehta	Managing Director	10yrs	₹2.40m	5.23% ₹ 259.9m
Bhavin Mehta	Whole-time Director	7.2yrs	₹8.40m	15.69% ₹ 779.8m
Hemang Engineer	Independent & Non Executive Director	16.4yrs	₹25.00k	geen gegevens
Vasudev Murti	Non-Executive Independent Director	6.7yrs	₹30.00k	geen gegevens
Venkita Rajan	Independent Non-Executive Director	6.4yrs	₹5.00k	geen gegevens
Dipen Jain	Non- Executive Independent Director	less than a year	geen gegevens	geen gegevens

7.2yrs

Gemiddelde duur

65yo

Gemiddelde leeftijd

Ervaren bestuur: De raad van bestuur van KILITCH wordt beschouwd als ervaren (gemiddelde ambtstermijn 7.2 jaar).

Kilitch Drugs (India) Beheer

Beheer criteriumcontroles 3/4

Belangrijke informatie

Recente managementupdates

Kilitch Drugs (India) Limited Approves Change Designation of Mira Bhavin Mehta from Whole Time Director to Managing Director

Kilitch Drugs (India) Limited, Annual General Meeting, Sep 27, 2024

Shareholders Would Not Be Objecting To Kilitch Drugs (India) Limited's (NSE:KILITCH) CEO Compensation And Here's Why

Kilitch Drugs (India) Limited, Annual General Meeting, Sep 29, 2023

Insufficient new directors

Kilitch Drugs (India) Limited, Annual General Meeting, Sep 29, 2022

Recent updates

Second quarter 2025 earnings released: EPS: ₹5.36 (vs ₹2.93 in 2Q 2024)

Kilitch Drugs (India) Limited to Report First Half, 2025 Results on Nov 12, 2024

Kilitch Drugs (India) Limited Approves Change Designation of Mira Bhavin Mehta from Whole Time Director to Managing Director

Investor sentiment improves as stock rises 18%

Kilitch Drugs (India) Limited, Annual General Meeting, Sep 27, 2024

First quarter 2025 earnings released: EPS: ₹0.83 (vs ₹2.15 in 1Q 2024)

Kilitch Drugs (India) Limited to Report Q1, 2025 Results on Aug 08, 2024

Kilitch Drugs (India) Limited (NSE:KILITCH) Not Flying Under The Radar

Full year 2024 earnings released: EPS: ₹9.17 (vs ₹6.71 in FY 2023)

Here's Why Kilitch Drugs (India) (NSE:KILITCH) Can Manage Its Debt Responsibly

Third quarter 2024 earnings released: EPS: ₹1.85 (vs ₹1.52 in 3Q 2023)

Kilitch Drugs (India) Limited (NSE:KILITCH) Looks Just Right With A 26% Price Jump

Investor sentiment improves as stock rises 16%

We Ran A Stock Scan For Earnings Growth And Kilitch Drugs (India) (NSE:KILITCH) Passed With Ease

Investor sentiment improves as stock rises 16%

Investors Shouldn't Be Too Comfortable With Kilitch Drugs (India)'s (NSE:KILITCH) Earnings

Second quarter 2024 earnings released: EPS: ₹2.93 (vs ₹1.56 in 2Q 2023)

Investor sentiment improves as stock rises 21%

Shareholders Would Not Be Objecting To Kilitch Drugs (India) Limited's (NSE:KILITCH) CEO Compensation And Here's Why

These 4 Measures Indicate That Kilitch Drugs (India) (NSE:KILITCH) Is Using Debt Reasonably Well

Kilitch Drugs (India) Limited to Report Fiscal Year 2024 Results on May 30, 2024

First quarter 2024 earnings released: EPS: ₹2.15 (vs ₹1.34 in 1Q 2023)

Kilitch Drugs (India) Limited, Annual General Meeting, Sep 29, 2023

Kilitch Drugs (India) Limited to Report Q1, 2024 Results on Aug 11, 2023

New minor risk - Shareholder dilution

Full year 2023 earnings released: EPS: ₹6.71 (vs ₹4.73 in FY 2022)

Kilitch Drugs (India) Limited to Report Q4, 2023 Results on May 29, 2023

Here's Why Kilitch Drugs (India) (NSE:KILITCH) Has Caught The Eye Of Investors

Investor sentiment improves as stock rises 21%

Investor sentiment improves as stock rises 15%

Third quarter 2023 earnings released: EPS: ₹1.52 (vs ₹0.72 in 3Q 2022)

Kilitch Drugs (India) Limited to Report Q3, 2023 Results on Feb 14, 2023

Second quarter 2023 earnings released: EPS: ₹1.56 (vs ₹1.39 in 2Q 2022)

Insufficient new directors

First quarter 2023 earnings released: EPS: ₹1.34 (vs ₹0.76 in 1Q 2022)

Kilitch Drugs (India) Limited, Annual General Meeting, Sep 29, 2022

Kilitch Drugs (India) (NSE:KILITCH) Could Easily Take On More Debt

Investor sentiment improved over the past week

Kilitch Drugs (India) Limited Announces Management Changes

Full year 2022 earnings released: EPS: ₹4.73 (vs ₹2.37 in FY 2021)

Kilitch Drugs (India) Limited to Report Q4, 2022 Results on May 26, 2022

Insufficient new directors

Kilitch Drugs (India) Limited Announces Resignation of Princy Asati as Company Secretary & Compliance Officer

Here's Why I Think Kilitch Drugs (India) (NSE:KILITCH) Might Deserve Your Attention Today

Investor sentiment improved over the past week

Third quarter 2022 earnings: Revenues and EPS in line with analyst expectations

Investor sentiment improved over the past week

Kilitch Drugs (India) Limited announced that it expects to receive INR 22.14375 million in funding

These 4 Measures Indicate That Kilitch Drugs (India) (NSE:KILITCH) Is Using Debt Reasonably Well

First quarter 2022 earnings released: EPS ₹0.76 (vs ₹0.86 loss in 1Q 2021)

Investor sentiment improved over the past week

Full year 2021 earnings released: EPS ₹2.37 (vs ₹0.55 in FY 2020)

Investor sentiment improved over the past week

Is Kilitch Drugs (India) (NSE:KILITCH) Using Too Much Debt?

New 90-day low: ₹87.85

Should Weakness in Kilitch Drugs (India) Limited's (NSE:KILITCH) Stock Be Seen As A Sign That Market Will Correct The Share Price Given Decent Financials?

Third quarter 2021 earnings released: EPS ₹1.43 (vs ₹0.62 in 3Q 2020)

Kilitch Drugs (India) Limited to Report Q3, 2021 Results on Feb 11, 2021

Is Kilitch Drugs (India) (NSE:KILITCH) Weighed On By Its Debt Load?

Kilitch Drugs (India) Limited to Report Q2, 2021 Results on Nov 13, 2020

New 90-day high: ₹106

New 90-day low: ₹83.75

First quarter earnings released

Full year earnings released - EPS ₹0.55

Kilitch Drugs (India) Limited to Report Q1, 2021 Results on Sep 15, 2020

Does Kilitch Drugs (India) Limited (NSE:KILITCH) Have A Place In Your Dividend Stock Portfolio?

New 90-day low - ₹85.85

New 90-day low - ₹87.20

Should Weakness in Kilitch Drugs (India) Limited's (NSE:KILITCH) Stock Be Seen As A Sign That Market Will Correct The Share Price Given Decent Financials?